JPS6341424A - Medicine against vomit or like - Google Patents
Medicine against vomit or likeInfo
- Publication number
- JPS6341424A JPS6341424A JP62192553A JP19255387A JPS6341424A JP S6341424 A JPS6341424 A JP S6341424A JP 62192553 A JP62192553 A JP 62192553A JP 19255387 A JP19255387 A JP 19255387A JP S6341424 A JPS6341424 A JP S6341424A
- Authority
- JP
- Japan
- Prior art keywords
- medicament according
- component contains
- dosage unit
- per dosage
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims description 30
- 230000008673 vomiting Effects 0.000 title claims description 8
- 229940079593 drug Drugs 0.000 title description 11
- 210000004916 vomit Anatomy 0.000 title 1
- 206010047700 Vomiting Diseases 0.000 claims description 12
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 10
- 229940102465 ginger root Drugs 0.000 claims description 10
- 239000001841 zingiber officinale Substances 0.000 claims description 10
- 239000002274 desiccant Substances 0.000 claims description 8
- 241000218628 Ginkgo Species 0.000 claims description 7
- 235000011201 Ginkgo Nutrition 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 5
- 244000194101 Ginkgo biloba Species 0.000 claims description 3
- 206010028813 Nausea Diseases 0.000 claims description 3
- 230000008693 nausea Effects 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008298 dragée Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 230000000202 analgesic effect Effects 0.000 claims 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 229960005489 paracetamol Drugs 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 239000007940 sugar coated tablet Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 description 7
- 201000003152 motion sickness Diseases 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 208000019695 Migraine disease Diseases 0.000 description 6
- 230000035935 pregnancy Effects 0.000 description 6
- 208000037175 Travel-Related Illness Diseases 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000009233 Morning Sickness Diseases 0.000 description 2
- 208000034850 Vomiting in pregnancy Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 229940124583 pain medication Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 206010003011 Appendicitis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010038776 Retching Diseases 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 241000234314 Zingiber Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000010649 ginger oil Substances 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/76—Salicaceae (Willow family), e.g. poplar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
Abstract
(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。(57) [Abstract] This bulletin contains application data before electronic filing, so abstract data is not recorded.
Description
【発明の詳細な説明】
本発明は、むかつき、あるいは嘔吐等に抗する医薬に関
する。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a medicament for combating nausea, vomiting, etc.
むかつき、および嘔吐は、良好な経過ならびに重大なｍ
い病気の両方により発生されることがある症状である。Nausea and vomiting are signs of a good course and serious malignancies.
This is a symptom that can be caused by both inflammatory and inflammatory diseases.
旅行病（乗り物酔い）におけるむかつき、および嘔吐の
原因は、例えば、錯綜したシステムの刺激感の過多に存
在する。確かに多くの人々は、異常な運動（興奮）形態
の作用に抗して他の人よりも抵抗力があるけれども、本
質的に全ての人が旅行病になる可能性がある。それゆえ
、この発病の症状を防止するために、多くの一般的な要
求が存在している。The causes of nausea and vomiting in travel sickness (motion sickness), for example, lie in overstimulation of complex systems. While it is true that many people are more resistant than others to the effects of abnormal forms of exercise (excitement), essentially everyone is susceptible to travel sickness. Therefore, there are many general demands to prevent the symptoms of this disease.
妊娠の第１月の間の嘔吐およびむかつきのメカニズムは
、今まで解明されることができていない。The mechanism of vomiting and retching during the first month of pregnancy has not been able to be elucidated until now.
しかも、これらの症状は治療することが難しい。Moreover, these symptoms are difficult to treat.
なぜなら、部分的理由としては、単一の作用物質（酵素
、ビタミン、ホルモン等）が各関係において有効である
とは思われないためであり、しかし全体の理由としては
特に、妊娠の期間中の薬剤の使用は可能な限り制限され
るべきだからである。This is because, in part, no single agent (enzyme, vitamin, hormone, etc.) is likely to be effective in each relationship, but the overall reason is that especially during pregnancy, This is because the use of drugs should be limited as much as possible.
むかつき、および嘔吐は、いわゆる偏頭痛の付随的徴候
であることもあるが、あるいは甲状腺の機能低下、腎孟
炎、急性盲腸炎、胆嚢炎等のごとき重大な病気に対する
症状であることもある。Nausea and vomiting may be incidental symptoms of so-called migraine headaches, or they may be symptoms of serious illnesses such as thyroid underfunction, nephritis, acute appendicitis, cholecystitis, etc.
むかつき、および嘔吐の症状の専らの治療は、当然、良
性または不明瞭な原因に関係するときのみ、すなわち、
例えば旅行病、妊娠の嘔吐（つわり）、または偏頭痛の
場合においてのみ適合性を備えているに過ぎない。旅行
病の症状に抗する予防においては、最近は、ショウガ科
の根茎に基礎を置く抗層吐剤が評判通りであることが判
っている。妊娠の嘔吐に対しては今日まで、良い効能が
あり且つ過度の副作用のない薬剤が存在していない。Exclusive treatment of symptoms of nausea and vomiting should, of course, only be used when related to benign or obscure causes, i.e.
For example, it is only applicable in cases of travel sickness, pregnancy vomiting (morning sickness), or migraines. In recent years, anti-emetic agents based on the rhizomes of the Zingiberaceae family have been found to be effective in preventing the symptoms of travel diseases. To date, there is no drug that has good efficacy and does not cause excessive side effects for pregnancy-induced vomiting.
偏頭痛の治療のため、特製の二裂および二つ折のイチョ
ウの乾燥剤（Ｅ ｘｔｒ、Ｇ ｉｎｋｇｏ ｂｉｌｏｂ
ａｅ ｅｒｏｔ 、 ５ｉｃｃ、 ）が既に、効果があ
るものとして認定されており、この場合、頭痛阻止が行
われている治療中の壱者は、全般的に存在する改冴作用
も感じることが報告されている。For the treatment of migraines, special bifid and bifold ginkgo bilob desiccant (Extr, G inkgo bilob)
ae erot, 5icc, ) has already been recognized as effective, and in this case, it has been reported that patients undergoing treatment for headache prevention also feel a generally present improving effect. ing.
本発明の課題は、むかつき、または嘔吐等に抗する医薬
を、特に旅行病（乗り物酔い）、妊娠の嘔吐（つわり）
、または偏頭痛の場合に治療に供することであり、当該
医薬は、今まで知られている薬剤よりも良い作用を有し
、ならびに／または副作用および病的危害を加えないも
のである。An object of the present invention is to provide a medicine to combat nausea, vomiting, etc., especially for travel sickness (motion sickness) and pregnancy vomiting (morning sickness).
, or for treatment in the case of migraine, the medicament having a better effect than hitherto known drugs and/or causing no side effects and morbid harm.
本発明によると、この課題は、ショウガの根茎（Ｒｈｌ
ｚｏｍａ Ｚ Ｉ！′＋ｇｌｂｅｒｉｓ ）および特
製の二裂および二つ折のイチョウの乾燥剤（Ｅ ｘＬｒ
、Ｇ ｉｎｋｇ。According to the present invention, this problem is solved by the ginger rhizome (Rhl).
zoma Z I! '+glberis) and special bifid and bifold ginkgo desiccant (E xLr
, G inkg.
ｂｉｌｏｂａｅ ｅ ｆｏｌ 、 ５Ｉｃｃ、 ）に成
分を有する医薬により解決される。The problem can be solved by a drug containing the following ingredients: bilobae fol, 5Icc, ).
本発明の特に有利な実施例は特許請求の範囲から明らか
になる。Particularly advantageous embodiments of the invention emerge from the claims.
植物性の作用物質（酵素、ビタミン、ホルモン等）であ
る薬用ショウガ根（Ｒｈｌｚｏｍａ ＺＩＨＩｂｃｒ
ｌｓ ；リツオーマ・ツィンギベリス）および特製の
二裂および二つ折のイチョウの乾燥剤（Ｅ ｘｔｒ。Medicinal ginger root (Rhlzoma ZIHIbcr), which is a plant-based active substance (enzymes, vitamins, hormones, etc.)
ls; Rhituoma zingiberis) and special bilobed and bifold ginkgo desiccant (Extr.
Ｇｉｎｋｇｏ ｂｌｌｏｂａｃ ｅ ｒｏｌ 、 ５
ｉｃｃ、 ；エクストラ・ギンクゴ・ピロベニ・工・
フォーリス・ズイカティーフ）の両方の本発明による組
合わせは、今までの使用要件における個々の作用物質の
作用、すなわち薬用ショウガ根による旅行病および特製
の二裂および二つ折のイチョウの乾燥剤による偏頭痛の
作用を共働させて驚異的に強化する結果となることが証
明されている。同時に、患者のより良い応諾が期待され
る。なぜなら、本発明の医薬でなければ、両方の適応症
の範囲において少なくとも２つの薬剤の投薬が必要とな
るからである。同時に、妊娠のむかつき及び嘔吐の治療
のための高い作用を有し且つ危険でない薬剤が最初に治
療に供される。Ginkgo blobacerol, 5
icc, ；extra・ginkugo・piroben・・
The combination according to the invention of both of the following (Foulis zuikatif) is effective for the effects of the individual active substances in the requirements of use up to now, namely travel sickness with the medicinal ginger root and migraine with the special bifid and bifid ginkgo desiccant. It has been proven that the effects of these two factors work together to amazingly strengthen the effects of the two. At the same time, better patient compliance is expected. This is because, without the medicament of the present invention, administration of at least two drugs would be required for both indications. At the same time, highly effective and non-hazardous drugs for the treatment of nausea and vomiting of pregnancy are first offered for treatment.
既に記述された適応症と並んで、本発明による医薬は、
（年齢の条件付きで）目眩、耳鳴り、または集中力の弛
緩等にも有効である。特に、偏頭痛の治療においては、
例えばＰ ａｒａｃｅｔａａｏｌ （バラセタモール：
解熱鎮痛薬）のような特別の苦痛薬（鎮痛剤）、あるい
は、ここでも植物性の作用物質に立ち帰るために、Ｃｏ
ｒｔｅｘ ５ａｌｌｃｉｓ （皮層サリシン）のような
特別の苦痛薬の追加の混合物が役に立つことが証明され
ている。Alongside the indications already described, the medicament according to the invention
It is also effective (with age conditions) for dizziness, tinnitus, or lack of concentration. Especially in the treatment of migraines,
For example, Paracetaol (Varacetamol:
Co
Additional admixtures of special pain medications such as rtex 5allcis (cortical salicin) have proven helpful.
その他、Ｒｈｊｚｏｍａ Ｚｉｎｇ！ｂｃｒｌｓ Ｐ
ｔ１ｃｎｙｌａｌｋａｎｏｎｅ （Ｇｉｎｇｅｔｏｌ
ｅ） −（リツ丁−マ・ツインギベリス・フェノールア
ルカノーネ（ギンガオーレ：ショウガ油））を含むこと
も可能であり、これはＰ ｒｏｓｔａｇｌａｎｄｌｎｂ
ｌｏｓｙｎｔｈｅｓｅ （プロスタグランデイン・ビ
オズインテーゼ）を抑制する。これは、今まで、薬剤と
して役立てていられない薬剤の二次的作用であり、これ
は、例えば、伝統的な鎮痛薬の評価の際に価値があるも
のである。Others, Rhjzoma Zing! bcrls P
t1cnylalkanone (Gingetol
e) It is also possible to contain -(Ritucho-Ma tsingiberis phenolalkanone (gingaole: ginger oil)), which is Prostaglandlnb
Inhibits losynthese (prostaglandin biosynthesis). This is a secondary effect of drugs that has hitherto been of no use as a drug, and is of value in the evaluation of traditional analgesics, for example.
投薬の単位は、特に、散薬の使用の際には、約３０ｍｇ
の特製の二裂および二つ折のイチョウの乾燥剤および約
５００ ｍｇの薬用ショウガ根であり、またエキスの使
用の際には、前記特製の二裂および二つ折のイチョウの
乾燥剤に加えて５０ｍｇの薬用ショウガ根が意のままに
役立てられるはずである。苦痛薬との組合わせにおいて
、これらは、投薬単位つき５００ ｍｇの持ち分を有す
る。そのような単位は、毎日３回服用されるべきであり
、ひどい場合には毎日６回服用されるべきである。The dosage unit is approximately 30 mg, especially when using powdered medicines.
special bifid and bifid ginkgo biloba desiccant and about 500 mg of medicinal ginger root, and when using the extract, in addition to the special bifid and bifid ginkgo biloba desiccant, about 50 mg of medicinal ginger root. The medicinal ginger root can be used at will. In combination with pain medications, these have a stock of 500 mg per dosage unit. Such units should be taken 3 times daily, and in severe cases 6 times daily.
前記薬剤（製剤）は、カプセル、滞留もしくは貯留され
た糖衣錠剤の形態で、または当該物質の流動性のある調
合剤として投薬されることができる。The drug (formulation) can be administered in the form of capsules, dregs or dragee tablets, or as a free-flowing preparation of the substance.
前記の説明におけるもの、および本発明の明確な特徴に
おけるもの、個々のもの、ならびに本発明の実施のため
の任意の組合わせにおけるものは、本質的に本発明の異
なる実施例中に存在し得るものである。What is in the foregoing description and what is in the defining features of the invention, both individually and in any combination for the implementation of the invention, may exist in essentially different embodiments of the invention. It is something.
Claims (12)
ｇｉｂｅｒｉｓ）および特製の二裂および二つ折のイチ
ョウの乾燥剤（Ｅｘｔｒ．Ｇｉｎｋｇｏｂｉｌｏｂａｅ
ｅｒｏｌ．ｓｉｃｃ．）であることを特徴とするむかつ
き、または嘔吐等に抗する医薬。(1) The ingredient is medicinal ginger root (RhizomaZin).
giberis) and special bifid and bifold ginkgo desiccant (Extr.
erol. sicc. ) A medicine to combat nausea, vomiting, etc.
につき、３００ｍｇおよび７００ｍｇの間の薬用ショウ
ガ根を含有していることを特徴とする特許請求の範囲第
１項記載の医薬。2. Medicament according to claim 1, characterized in that said component contains between 300 and 700 mg of medicinal ginger root per dosage unit when used as a powder.
ショウガ根を含有していることを特徴とする特許請求の
範囲第２項記載の医薬。(3) A medicament according to claim 2, characterized in that said component contains 500 mg of medicinal ginger root per dosage unit.
位につき、１０ｍｇおよび１００ｍｇの間の薬用ショウ
ガ根を含有していることを特徴とする特許請求の範囲第
１項記載の医薬。4. Medicament according to claim 1, characterized in that said component contains between 10 and 100 mg of medicinal ginger root per dosage unit when used as an extract.
位につき、５０ｍｇの薬用ショウガ根を含有しているこ
とを特徴とする特許請求の範囲第４項記載の医薬。(5) A medicament according to claim 4, characterized in that said component contains 50 mg of medicinal ginger root per dosage unit when used as an extract.
０ｍｇの間の特製の二裂および二つ折のイチョウの乾燥
剤を含有していることを特徴とする特許請求の範囲第１
項から第５項のいずれか１項に記載の医薬。(6) the ingredient is 20 mg and 4 mg per dosage unit;
Claim 1 characterized in that it contains between 0 mg of a special bilobed and bifold ginkgo desiccant.
The medicament according to any one of items 5 to 5.
二裂および二つ折のイチョウの乾燥剤を含有しているこ
とを特徴とする特許請求の範囲第６項記載の医薬。(7) A medicament according to claim 6, characterized in that said component contains 30 mg of special bilobed and bifold ginkgo biloba dessicant per dosage unit.
ることを特徴とする特許請求の範囲第１項から第７項の
いずれか１項に記載の医薬。(8) The medicament according to any one of claims 1 to 7, characterized in that the ingredient has an additional ingredient that is an analgesic.
ｌｉｃｉｓ）またはパラセタモール（Ｐａｒａｃｅｔａ
ｍｏｌ）であることを特徴とする特許請求の範囲第８項
記載の医薬。(9) The analgesic is derived from bark zyritin (CortexSa).
licis) or paracetamol (Paraceta
9. The medicament according to claim 8, wherein the medicament is mol).
の鎮痛剤を含有していることを特徴とする特許請求の範
囲第８項または第９項記載の医薬。(10) A medicament according to claim 8 or 9, characterized in that said component contains between 200 and 800 mg of analgesic.
ることを特徴とする特許請求の範囲第１０項記載の医薬
。(11) The medicament according to claim 10, wherein the component contains 500 mg of an analgesic.
た糖衣錠剤として、または両方の物質の流動性のある調
合剤として用意されていることを特徴とする特許請求の
範囲第１項から第１１項のいずれか１項に記載の医薬。(12) Claims 1 to 11, characterized in that the medicament is provided as a capsule, a retained or pooled sugar-coated tablet, or as a fluid preparation of both substances. The medicament according to any one of the above.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3626128.9 | 1986-08-01 | ||
| DE19863626128 DE3626128A1 (en) | 1986-08-01 | 1986-08-01 | Pharmaceutical composition for nausea, vomiting or the like |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS6341424A true JPS6341424A (en) | 1988-02-22 |
Family
ID=6306515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62192553A Pending JPS6341424A (en) | 1986-08-01 | 1987-07-31 | Medicine against vomit or like |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JPS6341424A (en) |
| DE (2) | DE3645254C2 (en) |
| FR (1) | FR2602144B1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07509494A (en) * | 1993-05-28 | 1995-10-19 | アロウディーン リミテッド | Novel anti-anxiety drug |
| KR20030008446A (en) * | 2001-07-18 | 2003-01-29 | 정영내 | morning sickness relief compositions of which chief ingredient is ginger |
| CN104623594A (en) * | 2015-01-09 | 2015-05-20 | 李培良 | Traditional Chinese medicinal composition for treating vomiting and diarrhea and preparation method of traditional Chinese medicinal composition |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2986136B1 (en) | 2013-03-15 | 2020-08-12 | Mars, Incorporated | Composition and method for preventing, reducing, alleviating, or treating idiopathic vomiting |
| JP6215443B2 (en) | 2013-03-15 | 2017-10-18 | マース インコーポレーテッドＭａｒｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Compositions and methods for preventing, reducing, alleviating or treating idiopathic vomiting |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3338995A1 (en) * | 1983-10-27 | 1985-05-09 | Dr. Willmar Schwabe GmbH & Co, 7500 Karlsruhe | MEDICINAL PRODUCTS CONTAINING BILOBALID |
| JPS559021A (en) * | 1978-07-04 | 1980-01-22 | Kodama Kk | Physiologically active substance from japanese ginger, its preparation, and drug comprising it |
| JPS5683416A (en) * | 1979-12-11 | 1981-07-08 | Lion Corp | Composition for oral cavity |
| FR2518406A1 (en) * | 1981-12-22 | 1983-06-24 | Prodipharm | NOVEL PROCESS FOR OBTAINING VASO-ACTIVE SUBSTANCES EXTRACTED FROM GINKGO SHEETS |
| FR2583640A1 (en) * | 1985-06-24 | 1986-12-26 | Berdal Pascal | Pharmaceutical compositions for vasculotropic and antisclerotic use |
-
1986
- 1986-08-01 DE DE3645254A patent/DE3645254C2/en not_active Expired - Fee Related
- 1986-08-01 DE DE19863626128 patent/DE3626128A1/en active Granted
-
1987
- 1987-07-15 FR FR8709944A patent/FR2602144B1/en not_active Expired
- 1987-07-31 JP JP62192553A patent/JPS6341424A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07509494A (en) * | 1993-05-28 | 1995-10-19 | アロウディーン リミテッド | Novel anti-anxiety drug |
| KR20030008446A (en) * | 2001-07-18 | 2003-01-29 | 정영내 | morning sickness relief compositions of which chief ingredient is ginger |
| CN104623594A (en) * | 2015-01-09 | 2015-05-20 | 李培良 | Traditional Chinese medicinal composition for treating vomiting and diarrhea and preparation method of traditional Chinese medicinal composition |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2602144A1 (en) | 1988-02-05 |
| DE3645254C2 (en) | 1994-06-09 |
| FR2602144B1 (en) | 1989-06-09 |
| DE3626128A1 (en) | 1988-02-04 |
| DE3626128C2 (en) | 1992-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5156845A (en) | Dry mouth lozenge | |
| Girling et al. | Adverse reactions to rifampicin | |
| US20160166631A1 (en) | Nutraceutical combination for prevention and treatment of type 2 diabetes | |
| IE59066B1 (en) | Controlled release potassium chloride | |
| KR20000070733A (en) | Use of gastrointestinal lipase inhibitors | |
| JPS59112948A (en) | Cholesterol level lowering agent | |
| US6017946A (en) | Serotonin containing formulation for oral administration and method of use | |
| Savin | Systemic ketoconazole in tinea versicolor: a double-blind evaluation and 1-year follow-up | |
| JPS6341424A (en) | Medicine against vomit or like | |
| JPS5938203B2 (en) | A therapeutic agent for cerebral circulation disorders whose main ingredient is coenzyme Q. | |
| US20070048367A1 (en) | Herbal composition for treating morning sickness | |
| US4260600A (en) | Method of treating depression | |
| PT2877192T (en) | Compositions for treatment of cancer-related fatigue | |
| KR20070086007A (en) | Medicinal composition for treating diabetes | |
| DK165966B (en) | IMPROVED PIROXICAM CONTAINING ANTI-INFLAMMATORY PREPARATION | |
| Sane et al. | The effect of a polyherbal oral formulation in the management of essential hypertension: an open label, pilot clinical study | |
| JP2003159028A (en) | Food for curing pollinosis | |
| McEwen | Phenylpropanolamine‐associated hypertension after the use of “over‐the‐counter” appetite‐suppressant products | |
| JPH0213647B2 (en) | ||
| US4493827A (en) | Method of inducing sleep | |
| Davydov et al. | Stevens-Johnson syndrome with Ginkgo biloba | |
| JPH0680564A (en) | Anti-pigmentation agent | |
| Evans et al. | A multi-centre trial of mazindol (‘Teronac’) in general practice in Ireland | |
| JP5241127B2 (en) | Analgesic composition | |
| GB2133285A (en) | Pharmaceutical compositions |